Should I have disease-modifying therapy for multiple sclerosis?

References

Citations

1. Sadiq SA (2005). Multiple sclerosis. In LP Rowland, ed., Merritt's Neurology, 11th ed., pp. 941–963. Philadelphia: Lippincott Williams and Wilkins.

2. Durelli L, et al. (2002). Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet, 359(9316): 1453–1460.

3. Panitch H, et al. (2002). Randomized, comparative study of interferon beta-1a treatment regimens in MS: The evidence trial. Neurology, 59(10): 1496–1506.

4. Stuart WH, Vermersch P (2004). Concomitant therapy for multiple sclerosis. Neurology, 63(Suppl 5): S28–S34.

5. Multiple Sclerosis Society of Canada (1999). Consensus statement urges early treatment and wider access for MS drugs. Multiple Sclerosis Society of Canada. Available online: http://www.mssociety.ca/en/research/DMT991209.htm.

Author:	Douglas Dana Shannon Erstad, MBA/MPH	Last Updated: August 14, 2006
Medical Review:	Adam Husney, MD - Family Medicine Kathleen Romito, MD - Family Medicine Colin Chalk, MD, CM, FRCPC - Neurology Barrie J. Hurwitz, MD - Neurology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.